Pharmaceutical research and development (R&D) is vital for innovation, with industry spending increasing over the years. AI has been touted as a solution to productivity issues in R&D, and the next frontier is AI foundation models that have the potential to transform the pharma industry. These models are trained on massive datasets and show emergent intelligence, making them versatile for various tasks in drug discovery. RNA foundation models are particularly promising for driving R&D improvements. Collaboration between computational scientists and biologists is essential for success. The business case for foundation models is strong, especially with looming patent cliffs on top drugs. Brendan Frey, Chief Innovation Officer of Deep Genomics, has made significant contributions to AI in biomedical research.
Source link
RNA Foundation Models to Improve Pharma R&D Productivity
